News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceapro Inc. (CV:CZO) Reports First Quarter 2010 Financial Results



5/10/2010 12:38:48 PM

EDMONTON, ALBERTA--(Marketwire - May 10, 2010) - Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today released financial and operating results for the first quarter ended March 31, 2010.

FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2010


--  Total sales of $1,155,000 compared to $1,502,000 in 2009, a decrease of
23%. There were no sales to the cyclical veterinary sector during this
quarter and there was a reduction in the average realized US/Canadian
exchange rate from $1.25 in 2009 to $1.04 in 2010.
--  Gross margin of $463,000 versus a gross margin of $852,000 in 2009, a
decrease of 46% due to lower sales of veterinary products, lower
realized US/Canadian exchange rates, and the sale of lower margin
products.
--  Income from operations of $94,000 compared to $233,000 in 2009
--  Net loss amounted to $49,000 or $0.00 per share compared to a net income
of $103,000 or $0.00 per share for 2009, This net loss of $49,000 is
after non cash expenses of $7,500 for accretion on convertible
debentures, $22,000 for stock based compensation, and $54,000 for
amortization.
--  General and administration and marketing expenses decreased by $99,000
or 25% and $39,000 or 65% respectively compared to 2009 as the Company
reduced costs and applied strict cash control measures.

"Results obtained in the first quarter of 2010 are encouraging and lead us to believe that the tough economic times experienced in the personal care industry may be behind us. After taking into account the decrease in sales to the veterinary market and the sharply lower US/Canadian exchange rate, sales volumes to our core personal care sector actually increased from the strong 2009 first quarter., We are very pleased to have started year 2010 in such a strong manner said Gilles Gagnon, Acting President & CEO. "With the tremendous improvements achieved at our production facilities as well as with our technology, we are now in a position to deliver higher volumes of existing products while developing new ones both in house and through planned collaborations with state of the art facilities and world class scientists to develop new in-vitro and ex-vivo dermatological data. These studies will include investigating relevant genetic markers that are associated with inflammation skin diseases, dermal penetration of actives and protection of structural skin proteins. " he added.

The complete audited annual consolidated financial statements are available for review on SEDAR at http://sedar.com/Ceapro and on the Company's website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.


CEAPRO INC.
Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
and Deficit
Unaudited




Three Months and Quarter Ended March 31
----------------------------------------------------------------------------
2010          2009
----------------------------------------------------------------------------

Revenue
Sales                                           $ 1,154,862   $ 1,501,909
Cost of goods sold                                  692,118       650,409
----------------------------------------------------------------------------
Gross margin                                        462,744       851,500
----------------------------------------------------------------------------

Expenses
General and administration                          290,673       390,322
Royalties                                            13,194       138,027
Sales and marketing                                  21,169        60,300
Amortization                                          8,528         9,928
Interest on convertible debenture                    10,000             -
Accretion on convertible debenture                    7,500             -
Interest on long-term debt                           18,144        19,914
----------------------------------------------------------------------------

369,208       618,491
----------------------------------------------------------------------------
Income from operations                                 93,536       233,009

Other income (expenses)
Research and product development                   (138,128)     (135,572)
Other income (expenses)                              (4,240)        5,339
----------------------------------------------------------------------------

(142,368)     (130,233)
----------------------------------------------------------------------------
Comprehensive income(loss) before income taxes        (48,832)      102,776

Income Taxes
Current                                              22,000        57,000
Reduction as a result of applying non-capital
losses forward
against the current period's taxable income         (22,000)      (57,000)
----------------------------------------------------------------------------


NET INCOME (LOSS) AND COMPREHENSIVE INCOME
(LOSS)
FOR THE PERIOD                                        (48,832)      102,776
Deficit, beginning of period                       (7,390,890)   (7,321,541)
----------------------------------------------------------------------------
Deficit, end of period                            $(7,439,722)  $(7,218,765)
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Net income (loss) per share:
Basic                                           $     (0.00)  $      0.00
----------------------------------------------------------------------------
Diluted                                         $     (0.00)  $      0.00
----------------------------------------------------------------------------

Weighted average number of common shares
outstanding                                      51,710,063    47,050,063
----------------------------------------------------------------------------

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Ceapro Inc.
Branko Jankovic
Vice President and CFO
780-917-8376 (Edmonton)
bjankovic@ceapro.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES